György S. Reusz

Dr. György S. Reusz


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2012 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
RSRukshana Shroff
Rukshana Shroff
ADArianna Dégi
Arianna Dégi
AKAndrea Kerti
Andrea Kerti
ÉKÉva Kis
Éva Kis
OCOrsolya Cseprekál
Orsolya Cseprekál
GRGyörgy S. Reusz
György S. Reusz

19 October 2022 in Pediatric Nephrology
Verified
Journal Article
Open access
PDF file
OHOrsolya Horváth
Orsolya Horváth
Attila SzaboAttila Szabo
Attila Szabo
GRGyörgy S. Reusz
György S. Reusz
Given the wide diversity of causes of hematuria, ranging from simple urinary tract infections with rapid recovery to severe glomerulonephritis with fast decline in kidney function, it is essential to recognize the underlying disease. The first objective of the assessment is to determine whether the cause of the hematuria is medically significant. The combination of hematuria with proteinuria, the presence of hypertension, or worsening kidney function can represent signs of progressive kidney disease. Differentiating the various causes of hematuria is often simple and obvious based on the clinical signs and gross appearance of the urine. However, in some instances, additional non-invasive investigations, such as ultrasound imaging, urinary red cell morphology, measurement of calcium and other solutes in the urine, evaluation of kidney function, and protein excretion, are needed to elucidate the nature of the hematuria. Taking a detailed family history can help in establishing the underlying cause in cases of familial hematuria. On the other hand, the decision to perform a kidney biopsy in children with asymptomatic hematuria remains a challenging issue for clinicians. Ultimately, the frequency of diagnosis of glomerular involvement causing hematuria may depend on the threshold for performing a kidney biopsy. The following review will focus on the diagnostics of hematuria, starting with difficulties regarding its definition, followed by various means to differentiate between urinary, glomerular, and other causes, and finally reviewing the most common diseases that, due to their frequency or their effect on kidney function, present a diagnostic challenge in everyday practice.

Verified
Journal Article
Open access
PDF file
DBDora Bianka Balogh
Dora Bianka Balogh
AMAgnes Molnar
Agnes Molnar
ADArianna Degi
Arianna Degi
ATAkos Toth
Akos Toth
LLLilla Lenart
Lilla Lenart
AFAndrea Fekete
Andrea Fekete
Diabetic cardiovascular complications are associated with up to 50% mortality, and current therapies are not effective enough. Renin–angiotensin–aldosterone system inhibitors (RAASis) are the standard of care for diabetic patients with hypertension and albuminuria. Based on our previous studies reporting the renoprotective effects of low-dose RAASis, here, we hypothesized that low-dose RAASi treatment has cardioprotective and antifibrotic benefits in type 1 diabetes mellitus (T1DM). After five weeks of T1DM, adult male Wistar rats received low doses of ramipril, losartan, or eplerenone for two weeks. Heart rate, blood pressure, and pulse wave velocity (PWV) were recorded. Aortic intima–media thickness (IMT), collagen accumulation, and myocardial fibrosis were assessed. All RAASis reduced PWV elevation, prevented the progression of myocardial fibrosis, and normalized B-type natriuretic peptide, troponin I, and fibroblast growth factor 23 levels without affecting blood pressure. Interestingly, only eplerenone reversed the decline in Klotho levels and reduced IMT and fibrosis in the media of the aorta. Our comparative analysis suggests that mineralocorticoid receptor antagonists, particularly eplerenone, may offer superior efficacy in halting both the arterial and the myocardial injuries in T1DM compared to angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers.

16 July 2013 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
ADArianna Dégi
Arianna Dégi
AKAndrea Kerti
Andrea Kerti
OCOrsolya Cseprekál
Orsolya Cseprekál
ÉKÉva Kis
Éva Kis
PSPéter Sallay
Péter Sallay
GRGyörgy S. Reusz
György S. Reusz

1 June 2020 in Atherosclerosis
Verified
Journal Article
Open access
GRGyörgy S. Reusz
György S. Reusz
ABAdrienn Bárczi
Adrienn Bárczi
ADArianna Dégi
Arianna Dégi
OCOrsolya Cseprekál
Orsolya Cseprekál
ÉKÉva Kis
Éva Kis
PSPaolo Salvi
Paolo Salvi
Central pulse wave velocity (PWV) is a marker of arterial stiffness and is calculated by dividing the pulse wave travel distance by the transit time. However, there is no consensus as to the ideal distance measurement in children. The aim of our study was to identify the more reliable method to assess the distance measurement in the pediatric age. Carotid-femoral PWV was measured by applanation tonometry in 988 healthy children aged 6.5-19.9 years. Two different surface distances were assessed: the subtraction method, representing the distance from the suprasternal notch to the femoral artery minus the distance from the carotid artery to the suprasternal notch, and the direct method, consisting of 80% of the distance from the carotid artery to the femoral artery. Both these methods were compared with the actual path length determined by magnetic resonance imaging (MRI) in 31 children. Subtraction and direct methods were significantly correlated in patients aged <14 years and the corresponding PWV values showed a good agreement. In children aged ≥14 years, a significant difference between the two methods was found: subtraction - direct distance = -45 ± 28 mm, with a significant difference in the resulting PWV values = -0.57 ± 0.35 m/s (p < 0.0001). This result was confirmed by MRI, showing a 10% overestimation in distance measurement by the direct method in subjects aged ≥14 years, resulting in a significantly higher PWV. These data suggest a greater reliability of the subtractive method of distance measurement compared to the direct method in children.

1 July 2014 in Transplantation Proceedings
Verified
Journal Article
Closed access
ADA.A. Dégi
A.A. Dégi
EKE. Kis
E. Kis
AKA. Kerti
A. Kerti
OCO. Cseprekál
O. Cseprekál
ASA.J. Szabó
A.J. Szabó
GRGyörgy S. Reusz
György S. Reusz